Table 3.
Mean (95% CI) dose response to weight loss for outcome measures at 18-month follow-up. Adjusted for visit, gender, treatment group, baseline BMI, change in PASE scale, and baseline value of outcome.
| Variable | <5% (n= 74) |
≥5% (n=59) |
≥10% (n=76) |
≥20% (n= 31) |
P |
|---|---|---|---|---|---|
|
| |||||
| IL-6 (pg/mL) | 2.84 | 2.52 | 2.65 | 2.27 | 0.017* |
| 2.41,3.26 | 2.10,2.94 | 2.26,3.04 | 1.70,2.83 | ||
|
| |||||
| Knee Compressive Force (N) | 2750 | 2611 | 2444 | 2200 | <0.0001 |
| 2619,2880 | 2473,2749 | 2321,2567 | 2019,2381 | ||
|
| |||||
| WOMAC Pain (0–20) | 4.46 | 4.60 | 3.71 | 2.79 | 0.006 |
| 3.81,5.11 | 3.92,5.28 | 3.09,4.34 | 1.87,3.71 | ||
|
| |||||
| WOMAC Function (0–68) | 17.13 | 16.73 | 13.57 | 10.84 | 0.0005 |
| 15.15,19.11 | 14.70,18.76 | 11.67,15.47 | 8.07,13.61 | ||
|
| |||||
| 6 Minute Walk Distance (m) | 508 | 522 | 542 | 559 | <0.0001 |
| 496,520 | 510,534 | 530,553 | 543,576 | ||
|
| |||||
| SF-36 Physical (0–100) | 42.5 | 43.2 | 44.3 | 48.1 | 0.001 |
| 40.8,44.2 | 41.5,45.0 | 42.8,45.9 | 45.8,50.4 | ||
|
| |||||
| SF36 Mental (0–100) | 55.4 | 54.6 | 57.5 | 58.1 | 0.02 |
| 53.7,57.0 | 52.9,56.3 | 56.0,59.1 | 55.8,60.4 | ||
|
| |||||
| **PASE | 140 | 165 | 134 | 129 | 0.083 |
| 120,160 | 143,188 | 115,152 | 104,154 | ||
*
Significance based on log transformed data (not shown)
**
Not adjusted for change in PASE